Navigating the Thrombus Burden: Is Deferred Stenting the Answer to the No-Reflow Dilemma?

Abstract

Primary percutaneous coronary intervention (PCI) remains the gold-standard reperfusion strategy for patients presenting with acute ST-segment elevation myocardial infarction (STEMI) [1]. The therapeutic goal is straightforward yet time-critical: rapid restoration of coronary blood flow to salvage jeopardized myocardium and preserve ventricular function. Despite substantial advances in contemporary interventional cardiology, one of the most challenging obstacles encountered during primary PCI is the presence of a large intracoronary thrombus burden. Heavy thrombotic burden is frequently observed in STEMI and represents a major predictor of distal embolization, microvascular obstruction, and impaired myocardial reperfusion following intervention [2]. Even when successful epicardial coronary patency is achieved, embolization of thrombotic debris into the distal microcirculation can precipitate the dreaded no-reflow or slow-reflow phenomenon, resulting in persistent myocardial ischemia despite angiographically successful PCI [3]. Because no-reflow is strongly associated with larger infarct size, adverse ventricular remodeling, heart failure, and increased mortality, strategies aimed at preventing microvascular injury remain a critical area of investigation. In this context, deferred stenting has emerged as an appealing therapeutic approach [4]. Rather than immediate stent implantation, the strategy involves restoring initial coronary flow through thrombectomy, balloon angioplasty, or pharmacologic therapy, followed by a planned delay in stent deployment for 24–72 hours while intensive antithrombotic treatment facilitates thrombus resolution. The theoretical advantage is compelling: allowing time for thrombus burden to diminish may reduce distal embolization, improve microvascular perfusion, and ultimately enhance clinical outcomes. However, enthusiasm for routine adoption has been tempered by randomized evidence, most notably the DANAMI-3-DEFER trial, which failed to demonstrate a significant benefit of deferred stenting in an unselected STEMI population [5]. Consequently, the role of deferred stenting remains a subject of ongoing debate. In this issue of the Pakistan Heart Journal, Khan et al. contribute important real-world evidence from a high-volume tertiary care center in Pakistan [6]. In their retrospective observational cohort study of 450 STEMI patients with significant thrombus burden (TIMI thrombus grade ≥3), the investigators compared outcomes between immediate stenting (n=218) and deferred stenting (n=232). The findings are noteworthy. Deferred stenting was associated with a dramatic reduction in the incidence of no-reflow/slow-reflow compared with immediate stenting (5.2% vs. 28.9%, p<0.001), representing an approximately 82% relative risk reduction. This angiographic advantage translated into superior procedural success, with significantly higher rates of final TIMI grade 3 flow (94.8% vs. 71.1%). Importantly, patients undergoing deferred stenting also demonstrated greater recovery of left ventricular systolic function at both hospital discharge and six-month follow-up. While 30-day major adverse cardiovascular events (MACE) did not differ significantly between groups, the deferred strategy was associated with a substantial reduction in six-month MACE (10.8% vs. 20.2%, p=0.006). Equally reassuring was the observation that major bleeding events (BARC 3–5) and procedural complications were comparable between the two strategies, suggesting that the delayed approach did not compromise safety. Nevertheless, these encouraging findings should be interpreted with appropriate caution. As with all retrospective observational studies, residual confounding and selection bias cannot be excluded. A closer examination of baseline characteristics reveals a clinically meaningful imbalance between groups. Pre-procedural TIMI flow grade 0–1 was substantially more common among patients undergoing immediate stenting than among those selected for deferred intervention (23.9% vs. 5.2%, p<0.001). This difference suggests that patients in the immediate-stenting cohort may have presented with more severe ischemia, larger thrombus burden, or greater microvascular vulnerability at baseline, factors that independently increase the likelihood of no-reflow and adverse outcomes. Consequently, part of the observed benefit may reflect patient selection rather than the treatment strategy itself. Beyond methodological considerations, practical challenges must also be acknowledged. Deferred stenting necessitates a second catheterization procedure, prolonged hospitalization, increased healthcare resource utilization, and additional procedural costs. Furthermore, both physicians and patients may experience understandable concern regarding the potential risk of re-occlusion or recurrent ischemia during the waiting period. These logistical realities may limit widespread implementation, particularly in resource-constrained healthcare systems. Despite these limitations, the study by Khan et al. provides valuable insight into the management of STEMI patients with substantial thrombus burden. Their experience demonstrates that, in carefully selected patients and within an experienced interventional program, deferred stenting can be performed safely and may confer meaningful improvements in myocardial reperfusion, ventricular recovery, and intermediate-term clinical outcomes. The key message is not that deferred stenting should replace immediate stenting in all STEMI cases. Rather, it reinforces the importance of individualized decision-making. In patients where acceptable initial reperfusion has been achieved (TIMI flow ≥2) but a large residual thrombus remains, a strategy of temporary stabilization with intensive antithrombotic therapy followed by delayed stent implantation may offer an opportunity to protect the microcirculation and optimize myocardial recovery. As interventional cardiology continues to evolve toward increasingly personalized care, deferred stenting may find its greatest value not as a universal strategy, but as a selective tool for navigating the complex challenge of high thrombus burden and preventing the no-reflow phenomenon. References Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2018;39(2):119-77. DOI: 10.1093/eurheartj/ehx393 Sianos G, Papafaklis MI, Serruys PW. Angiographic thrombus burden classification in patients with ST-segment elevation myocardial infarction treated with percutaneous coronary intervention. J Invasive Cardiol. 2010;22(10 Suppl B):6B-14B. https://pubmed.ncbi.nlm.nih.gov/20947930/ Rezkalla SH, Kloner RA. No-reflow phenomenon. Circulation. 2002;105(5):656-62. DOI: 10.1161/hc0502.102867 Carrick D, Oldroyd KG, McEntegart M, Haig C, Petrie MC, Eteiba H, et al. A randomized trial of deferred stenting versus immediate stenting to prevent no- or slow-reflow in acute ST-segment elevation myocardial infarction (DEFER-STEMI). J Am Coll Cardiol. 2014;63(20):2088-98. DOI: 10.1016/j.jacc.2014.02.530 Kelbæk H, Høfsten DE, Køber L, Helqvist S, Kløvgaard L, Holmvang L, et al. Deferred versus immediate stenting in patients with ST-segment elevation myocardial infarction (DANAMI-3-DEFER): an open-label, randomised controlled trial. Lancet. 2016;387(10034):2199-206. DOI: 10.1016/S0140-6736(16)30072-1 Khan KA, Shah T, Shah HA, Shah SM, Rahim T, Khan MU, et al. Deferred Versus Immediate Stenting in ST-Segment Elevation Myocardial Infarction with High Thrombus Burden: A Retrospective Observational Cohort Study. Pak Heart J. 2026;59(03):[Ahead of Print]. DOI: 10.47144/phj.v59i3.3449